Lipid 5 |
Catalog No.GC49239
One-Click Copy Product Info
|
Lipid 5 is a new type of amino lipid .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2089251-33-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lipid 5 is a new type of amino lipid [1]. Lipid 5 is used to construct mRNA lipid nanoparticles, which have significantly higher delivery efficiency than MC3, faster in vivo clearance and better safety, making it suitable for long-term therapeutic mRNA delivery [2-3].
References:
[1]. Sabnis S, Kumarasinghe ES, Salerno T, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Molecular Therapy. 2018 Jun 6; 26(6): 1509-1519.
[2]. Burdette D, Ci L, Shilliday B, et al. Systemic exposure, metabolism, and elimination of [14C]-labeled amino lipid, Lipid 5, after a single administration of mRNA encapsulating lipid nanoparticles to Sprague-Dawley rats. Drug Metabolism and Disposition. 2023 Jul 1;51(7):804-812.
[3]. Ci L, Hard M, Zhang H, et al. Biodistribution of lipid 5, mRNA, and its translated protein following intravenous administration of mRNA-encapsulated lipid nanoparticles in rats. Drug Metabolism and Disposition. 2023 Jul 1;51(7):813-823.
This protocol describes the formulation of lipid nanoparticles (LNPs) using Lipid 5 for encapsulation and delivery of mRNA. This method is based on the microfluidic mixing approach. Specific conditions may require optimization depending on mRNA length, lipid batch, and application purpose [1–2].
1. Preparation of Reagents and Materials
Lipid 5 ( purity ≥ 95%), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), Cholesterol, PEG-lipid, mRNA.
2. Experimental Steps
(1) Lipid Stock Solution Preparation
Prepare lipid stock in ethanol at molar ratio of
Lipid 5:DSPC:Cholesterol:PEG-lipid = 50:10:38.5:1.5.
Dissolve each component in ethanol at defined concentrations (e.g., 10-20mM each).
Store at -20℃, protect from light.
(2) mRNA Aqueous Phase Preparation
Dissolve mRNA in 25-50mM sodium acetate buffer (pH = 5).
Final mRNA concentration: 0.2-0.5mg/mL.
Filter with 0.22μm membrane if needed.
(3) Microfluidic Mixing and LNP Assembly
Mix ethanol phase (lipids) and aqueous phase (mRNA) at 3:1 aqueous:ethanol ratio using a microfluidic mixer.
Flow rate: e.g., 12mL/min total flow (adjust as per device spec).
LNPs form spontaneously upon mixing.
(4) Post-processing and Purification
Dialyze product overnight in PBS (pH = 7.4) using dialysis cassette or use Amicon filter to exchange buffer and remove ethanol.
Final formulation should contain <5% ethanol and be in isotonic PBS.
Sterile filter using 0.22μm syringe filter before in vivo use.
Notes and Precautions
(1) Lipid 5 is sensitive to hydrolysis; avoid repeated freeze-thaw cycles.
(2) Maintain the pH of aqueous buffer ≤5 during mixing to ensure optimal encapsulation.
(3) Final LNPs should be characterized for size (80-100nm), PDI (<0.2), encapsulation efficiency (>90%), and pKa (~6.5).
(4) Store LNPs at 4℃ and use within 7 days for best activity.
(5) Endotoxin level should be ≤1EU/mL for in vivo applications
References:
[1]. Burdette D, Ci L, Shilliday B, et al. Systemic exposure, metabolism, and elimination of [14C]-labeled amino lipid, Lipid 5, after a single administration of mRNA encapsulating lipid nanoparticles to Sprague-Dawley rats. Drug Metabolism and Disposition. 2023 Jul 1;51(7):804-812.
[2]. Ci L, Hard M, Zhang H, et al. Biodistribution of lipid 5, mRNA, and its translated protein following intravenous administration of mRNA-encapsulated lipid nanoparticles in rats. Drug Metabolism and Disposition. 2023 Jul 1;51(7):813-823.
| Cas No. | 2089251-33-0 | SDF | |
| Canonical SMILES | OCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCCCCCC(OCCCCCCCCC)=O | ||
| Formula | C44H87NO5 | M.Wt | 710.2 |
| Solubility | DMSO : 100 mg/mL (140.81 mM; Need ultrasonic) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4081 mL | 7.0403 mL | 14.0805 mL |
| 5 mM | 281.6 μL | 1.4081 mL | 2.8161 mL |
| 10 mM | 140.8 μL | 704 μL | 1.4081 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)